Therxindex

The RX Index (Kozi Publishing LLC) — Two related GLP-1 price-and-access datasets published as dated files with full source attribution. (1) A price-access table, one row per medication-channel-price-type combination, with 14 fields including price_type, dose_or_term, eligibility_or_conditions, effective_date, verified_date, source_name, source_url, a footnote code and explanatory notes — capturing WAC list price, manufacturer self-pay, direct-to-consumer starting price, commercial-plus-savings-card floor, Medicare Part D cost-sharing, and IRA negotiated Maximum Fair Price with its future effe…

Therxindex offers (Alternative, Fundamental, Price) — The retrieved price-access CSV runs to roughly 19 KB of dense records, each carrying 14 fields with a named source, source URL, verified date and conditional notes — on the order of a hundred or more medication-by-channel price rows across multiple GLP-1 products and six-plus price types. The coverage tracker is the larger asset: state-level entries plus named carriers (Blue Cross Blue Shield of Michigan, Cigna, CVS Caremark template formulary among those visible), state plans and named employers, each with document citations and evidence grades, drawing on KFF, Mercer, IFEBP and Business Group on Health survey series with sample sizes and survey-wave provenance recorded. Filenames are dated (2026-09-24) and the tracker carries a research cutoff date, implying periodic re-publication and an accumulating backfile..

The employer coverage tracker is the commercially interesting one: it answers a question no other source in this pool touches — which specific carriers, PBMs and named employers have restricted or excluded GLP-1 coverage for weight loss, effective when, and on what authority. Buyers: employer benefits teams and brokers modeling GLP-1 spend and plan-design change; PBMs and payers tracking competitor formulary moves; pharma market-access teams measuring erosion of commercial obesity coverage against IRA-driven Medicare pricing; and consultants quantifying the shift of obesity-drug cost onto cash-pay and compounded channels as commercial coverage falls (the tracker's own series shows large-employer obesity-drug coverage declining from 72% to 60% across survey waves). The price table supports channel-level price-construction analysis and patient out-of-pocket modeling across WAC, self-pay, savings-card floor and IRA Maximum Fair Price, including forward-dated 2027 Part D basis prices.